The stock's fall snapped a six-day winning streak.

Retirement dreams often hinge on a robust portfolio, with $1 million as a coveted benchmark for financial security. Achieving ...

Eli Lilly's LLY short percent of float has risen 9.78% since its last report. The company recently reported that it has 8.03 million shares sold short, which is 1.01% of all regular shares that are ...

A growth-focused fund blending momentum and strong earnings. High upside potential with elevated volatility. Best for ...

While stock splits are far from easy to predict, two names stand out for their potential to do so going forward. Those stocks ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.